Skip to content

The Features Behind the Beneficial Effects of Interval-walking

The Features Behind the Beneficial Effects of Interval-walking

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02257190
Acronym
aIWS2
Enrollment
12
Registered
2014-10-06
Start date
2014-10-31
Completion date
2015-10-31
Last updated
2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Glycemic control, Exercise

Brief summary

A single bout of Interval-Walking (IW) exercise is superior to energy-expenditure and time-duration matched Continuous Walking (CW) exercise upon improving glycemic control. The reason IW is superior is unknown. This study will look into whether it is the larger peak intensity during IW or if it is the alternating exercise pattern that is responsible for the larger improvements seen. Subjects with type 2 diabetes will be included in a crossover, counter-balanced, controlled study, where each subject will undergo three trials. Trials will be identical except the following interventions: 1. One hour of rest (Con) 2. One hour of classical interval walking (repeated cycles of 3 min of fast and 3 min of slow walking; IW3) 3. One hour of fast alternating interval walking (repeated cycles of 1 min of fast and 1 min of slow walking; IW1). After the interventions subjects will undergo a standardized mixed meal tolerance test, with consecutive measurements of blood glucose, insulin and c-peptide.

Interventions

BEHAVIORALControl

One hour of rest.

BEHAVIORALIW3

A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking

BEHAVIORALIW1

A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes mellitus * Body mass index \> 18 but \< 40 m2/kg * Agreement to pause antidiabetic medication from 2 days before to after each trial

Exclusion criteria

* Pregnancy * Smoking * Use of exogenous insulin * Contraindication to increased levels of physical activity * Evidence of thyroid, liver, lung, heart or kidney disease

Design outcomes

Primary

MeasureTime frameDescription
Glycemic controlWithin the first 4 hours after the interventionsGlycemic control will be measured after each intervention. Subjects will receive a standardized mixed meal tolerance test (MMTT), and blood glucose values will be obtained during the test.

Secondary

MeasureTime frameDescription
Insulin secretionWithin the first 4 hours after the interventionsInsulin and C-peptide will be measured during the MMTT
Insulin sensitivityWithin the first 4 hours after the interventionsFrom the measurements og glucose and insulin during the MMTT, various indices of insulin sensitivity will be assessed

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026